<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Oppenheimer Touts Boston Scientific Corporation (BSX) as the Best Large-Cap MedTech</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Oppenheimer Touts Boston Scientific Corporation (BSX) as the Best Large-Cap MedTech</h1>
  <ul>
<li>Its competitive edge was the catalyst behind a 17% organic revenue growth in the second quarter of 2025 as earnings per share increased 23%.</li>
<li>The company has delivered a strong performance, with 21.44% revenue growth over the past 12 months.</li>
<li>In addition, the research firm has echoed the company’s projected 11%-13% compound annual growth rate outlook.</li>
<li>On September 8, analysts at Oppenheimer upgraded the stock to an ‘Outperform’ from Perform and reiterated a $125 price target.</li>
<li>READ NEXT: 11 Best Wind Power and Solar Stocks to Buy According to Analysts and 10 Best Robinhood Penny Stocks to Invest In.</li>
<li>Disclosure: None.</li>
<li>This article is originally published at Insider Monkey.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/oppenheimer-touts-boston-scientific-corporation-130330776.html">Source</a> · 2025-09-15T13:03:30+00:00</p>
</body>
</html>